|
|
|
|
 |
|
The reanalysis of the ESPS-2 trial in high risk patients by Professor Ralph L. Sacco is focussing on the efficacy of aspirin plus extended-release dipyridamole in preventing recurrent stroke in high-risk populations.
Trial Design
Project Objective
- Analyse clinical trial data from ESPS 2 to assess effectiveness of ER-DP/ASA vs ASA in various risk subgroups
Methodology
- Evaluate baseline subgroups in ESPS 2
Use baseline risk criteria from ESPS 2 to categorise and evaluate drug effect in low and high risk subgroups based upon different models (Framingham, Stroke Prognostic Index).
Outcomes
- Recurrent Stroke;
- Stroke or Vascular Events (MI and vascular death)
Results
Compared with aspirin alone, aspirin plus extended-release dipyridamole demonstrated a more pronounced efficacy in reducing the risk for stroke and vascular events among
- patients younger than 70 years;
- those with hypertension,
- prior stroke, or
- transient ischemic attack;
- current smokers;
- and those with any prior cardiovascular disease.
Relative hazard reductions favored the combination of aspirin plus extended-release dipyridamole, and were greatest for the high-risk Framingham Study group and the moderate-risk Stroke Prognostic Instrument II subgroup.
Relative Hazard Reductions for ASA/ER-DP vs. ASA
Among High-risk Subgroups Using Framingham Model
Relative Hazard Reductions for ASA/ER-DP vs. ASA
Among High-risk Subgroups Using Stroke Prognostic Index
Conclusion
Aspirin plus extended-release dipyridamole is more effective than aspirin alone at preventing stroke, and the difference in efficacy increases in higher-risk patients.
Abstract
Reference:
Sacco et al. Arch Neurol 2005; 62 (3): 403-408
|
|
 |
|
© 2005 Boehringer Ingelheim GmbH, Germany. All rights reserved.
|
|
|
|
|
|
